Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/IPO5_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/IPO5_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/IPO5_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/IPO5_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/IPO5_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/IPO5_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/IPO5_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/IPO5_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190018210 | Oral cavity | OSCC | positive regulation of protein localization to nucleus | 66/7305 | 87/18723 | 2.74e-12 | 1.10e-10 | 66 |
GO:190018015 | Oral cavity | OSCC | regulation of protein localization to nucleus | 93/7305 | 136/18723 | 3.46e-12 | 1.35e-10 | 93 |
GO:004232619 | Oral cavity | OSCC | negative regulation of phosphorylation | 214/7305 | 385/18723 | 2.30e-11 | 7.74e-10 | 214 |
GO:007190010 | Oral cavity | OSCC | regulation of protein serine/threonine kinase activity | 201/7305 | 359/18723 | 3.90e-11 | 1.27e-09 | 201 |
GO:000193319 | Oral cavity | OSCC | negative regulation of protein phosphorylation | 191/7305 | 342/18723 | 1.58e-10 | 4.62e-09 | 191 |
GO:003367317 | Oral cavity | OSCC | negative regulation of kinase activity | 140/7305 | 237/18723 | 2.74e-10 | 7.57e-09 | 140 |
GO:000646918 | Oral cavity | OSCC | negative regulation of protein kinase activity | 127/7305 | 212/18723 | 5.21e-10 | 1.37e-08 | 127 |
GO:00511709 | Oral cavity | OSCC | import into nucleus | 100/7305 | 159/18723 | 8.67e-10 | 2.15e-08 | 100 |
GO:00066069 | Oral cavity | OSCC | protein import into nucleus | 97/7305 | 155/18723 | 2.27e-09 | 5.30e-08 | 97 |
GO:00457864 | Oral cavity | OSCC | negative regulation of cell cycle | 206/7305 | 385/18723 | 4.28e-09 | 9.55e-08 | 206 |
GO:004682414 | Oral cavity | OSCC | positive regulation of nucleocytoplasmic transport | 45/7305 | 62/18723 | 8.26e-08 | 1.46e-06 | 45 |
GO:19045899 | Oral cavity | OSCC | regulation of protein import | 43/7305 | 63/18723 | 2.43e-06 | 3.06e-05 | 43 |
GO:00719013 | Oral cavity | OSCC | negative regulation of protein serine/threonine kinase activity | 72/7305 | 120/18723 | 2.53e-06 | 3.17e-05 | 72 |
GO:19040293 | Oral cavity | OSCC | regulation of cyclin-dependent protein kinase activity | 60/7305 | 98/18723 | 6.90e-06 | 7.56e-05 | 60 |
GO:00000793 | Oral cavity | OSCC | regulation of cyclin-dependent protein serine/threonine kinase activity | 58/7305 | 94/18723 | 6.92e-06 | 7.57e-05 | 58 |
GO:19045918 | Oral cavity | OSCC | positive regulation of protein import | 31/7305 | 43/18723 | 1.10e-05 | 1.14e-04 | 31 |
GO:00423068 | Oral cavity | OSCC | regulation of protein import into nucleus | 40/7305 | 60/18723 | 1.32e-05 | 1.33e-04 | 40 |
GO:00423078 | Oral cavity | OSCC | positive regulation of protein import into nucleus | 29/7305 | 41/18723 | 3.81e-05 | 3.37e-04 | 29 |
GO:00011019 | Oral cavity | OSCC | response to acid chemical | 74/7305 | 135/18723 | 1.38e-04 | 9.76e-04 | 74 |
GO:00432006 | Oral cavity | OSCC | response to amino acid | 64/7305 | 116/18723 | 2.96e-04 | 1.86e-03 | 64 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IPO5 | SNV | Missense_Mutation | rs9584741 | c.2731G>A | p.Glu911Lys | p.E911K | O00410 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
IPO5 | SNV | Missense_Mutation | rs371777975 | c.1615N>A | p.Asp539Asn | p.D539N | O00410 | protein_coding | tolerated(0.06) | possibly_damaging(0.867) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
IPO5 | SNV | Missense_Mutation | | c.3040T>C | p.Trp1014Arg | p.W1014R | O00410 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-GI-A2C8-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Adriamycin | SD |
IPO5 | SNV | Missense_Mutation | novel | c.780N>C | p.Glu260Asp | p.E260D | O00410 | protein_coding | tolerated(0.99) | benign(0.14) | TCGA-LL-A740-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
IPO5 | SNV | Missense_Mutation | novel | c.1470C>A | p.Asp490Glu | p.D490E | O00410 | protein_coding | tolerated(0.22) | possibly_damaging(0.517) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
IPO5 | SNV | Missense_Mutation | | c.28N>A | p.Glu10Lys | p.E10K | O00410 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.953) | TCGA-C5-A1BE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
IPO5 | SNV | Missense_Mutation | | c.1295G>C | p.Arg432Thr | p.R432T | O00410 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
IPO5 | SNV | Missense_Mutation | | c.1145T>C | p.Met382Thr | p.M382T | O00410 | protein_coding | tolerated(0.1) | benign(0.089) | TCGA-EX-A69M-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
IPO5 | SNV | Missense_Mutation | novel | c.1958N>T | p.Ser653Leu | p.S653L | O00410 | protein_coding | deleterious(0) | possibly_damaging(0.543) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
IPO5 | SNV | Missense_Mutation | rs566255473 | c.1688N>T | p.Ala563Val | p.A563V | O00410 | protein_coding | deleterious(0.03) | possibly_damaging(0.758) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |